US Patent 9,012,437: Claim Scope, Ozurdex Coverage and Dexamethasone Implant Patent Landscape

US Patent No. 9,012,437 covers a narrow method of treating specified posterior-segment eye conditions with an extruded, bioerodible dexamethasone implant. The claim requires a PLGA-type implant weighing approximately 500 to 1,000 micrograms, defined vitreous dexamethasone exposure thresholds, and delivery over at least three weeks. The patent is directed to the product and administration profile associated with the Ozurdex dexamethasone intravitreal implant, but its enforceable term has ended based on the underlying patent term.

The claims are narrower than a general patent on intravitreal dexamethasone. A potentially infringing product must satisfy the implant composition, manufacturing, size, pharmacokinetic, and treatment-condition limitations in combination.

What does US Patent 9,012,437 cover?

US Patent 9,012,437, titled “Biodegradable Implants for Treating Ocular Conditions,” claims a treatment method rather than a free-standing composition. The claimed method requires:

Implantation into the vitreous of the eye.
A bioerodible implant.
Dexamethasone as the active drug.
A bioerodible polymer matrix.
Initial vitreous exposure equivalent to at least approximately 0.05 micrograms per milliliter within about 48 hours.
Maintenance of at least approximately 0.03 micrograms per milliliter for at least three weeks.
Manufacture by extrusion.
A total implant weight of approximately 500 to 1,000 micrograms.
Treatment of macular edema, acute macular degeneration, retinal detachment, or proliferative vitreoretinopathy.

The independent claim uses “comprising” for the treatment method but states that the implant is “consisting of dexamethasone and a bioerodible polymer.” The latter language materially limits the implant composition. An accused implant containing additional substantive implant components could raise a non-infringement argument, depending on how the claim is construed and whether the additional component is considered incidental or material.

Patent identification

Field	US 9,012,437
Patent title	Biodegradable Implants for Treating Ocular Conditions
Patent type	Utility patent
Technology	Intravitreal bioerodible dexamethasone implant
Primary assignee lineage	Allergan, Inc., now within AbbVie
Active ingredient	Dexamethasone
Delivery site	Vitreous
Polymer	Bioerodible polymer, narrowed to PLGA in dependent claims
Manufacturing limitation	Extrusion
Implant mass	Approximately 500-1,000 micrograms
Drug loading in claim 5	Approximately 50%-80% by weight
Key commercial product	Ozurdex
Patent term	Ended in 2024 based on the underlying family term

The patent family is part of the broader Allergan/Oculex ocular drug-delivery portfolio. The relevant family includes earlier and later patents directed to biodegradable ocular implants, including US 7,691,001, US 7,767,174, and US 8,623,395. Family relationships and claim scope must be distinguished from the separate question of whether a particular patent was listed in the FDA Orange Book.

How do claims 1 through 5 narrow the patent scope?

Claim 1 contains all material limitations. Claims 2 through 5 progressively narrow the polymer and drug-loading requirements.

Claim	Added limitation	Practical effect
1	Dexamethasone, bioerodible polymer, vitreous delivery, exposure profile, extrusion, 500-1,000 micrograms, specified eye conditions	Broadest claim, but still highly constrained
2	PLGA copolymer	Excludes non-PLGA polymer systems
3	50/50 PLGA	Requires approximately equal lactic-acid and glycolic-acid components
4	Dexamethasone at approximately 10%-90% by weight	Defines a broad drug-loading range
5	Dexamethasone at approximately 50%-80% by weight	Narrowest claim and closest to a commercial 0.7-milligram implant

Claim 1: combined method and product limitations

Claim 1 is not satisfied merely because a physician administers dexamethasone into the eye. The method requires an implant with a specific delivery behavior and manufacturing history.

The main limitations are:

“Implanting into the vitreous” excludes delivery only to the anterior chamber, subconjunctival space, or periocular tissue.
“Bioerodible implant” requires degradation of the implant in the biological environment.
“Dexamethasone and a bioerodible polymer” identifies a drug-polymer matrix rather than a conventional liquid suspension.
The 48-hour and three-week concentration limitations impose a pharmacokinetic performance requirement.
“Produced by an extrusion method” introduces a process limitation into the claimed treatment method.
The 500-1,000 microgram limitation covers the total implant, not merely the dexamethasone quantity.
The condition list limits the claimed method to four named disease categories.

The “about” modifiers create numerical tolerance, but they do not eliminate the need to prove that the accused implant falls within the claimed ranges. The concentration limitations may be assessed through clinical pharmacokinetic data, in vitro release testing, animal studies, or other validated evidence, depending on the litigation record.

Claims 2 and 3: PLGA requirements

Claim 2 requires PLGA. A polylactic acid-only implant, polyglycolic acid-only implant, polycaprolactone implant, or nonpolymeric delivery system would not literally satisfy claim 2.

Claim 3 further requires a 50/50 PLGA copolymer. This limitation is important because PLGA degradation rate depends on the lactic-acid-to-glycolic-acid ratio, molecular weight, end-group chemistry, particle morphology, and implant geometry. A 75/25 or 65/35 PLGA formulation could avoid literal infringement of claim 3 while potentially remaining within claim 2.

Claims 4 and 5: drug loading

For a 500-1,000 microgram implant:

Claim 4 covers approximately 10%-90% dexamethasone by weight.
Claim 5 covers approximately 50%-80% dexamethasone by weight.

The corresponding approximate dexamethasone mass under claim 5 is:

Total implant mass	50% loading	80% loading
500 micrograms	250 micrograms	400 micrograms
700 micrograms	350 micrograms	560 micrograms
1,000 micrograms	500 micrograms	800 micrograms

Ozurdex contains a 0.7-milligram dexamethasone implant. The commercial implant’s total mass and drug loading must be evaluated against the patent’s total-weight and percentage limitations rather than against the nominal 0.7-milligram label strength alone. FDA describes Ozurdex as a biodegradable intravitreal implant containing dexamethasone in a PLGA matrix [2].

What formulation is associated with US 9,012,437?

The claimed formulation is a solid, biodegradable dexamethasone-polymer implant fabricated by extrusion. The commercial technology generally uses PLGA to control the release of dexamethasone after placement in the vitreous.

The key formulation variables include:

PLGA composition ratio.
Polymer molecular weight.
Polymer end groups.
Dexamethasone loading.
Implant dimensions.
Extrusion temperature and pressure.
Porosity and surface area.
Drug particle size.
Release-rate profile.
Sterilization method.

The patent does not cover every dexamethasone ocular product. A liquid intravitreal suspension, a non-bioerodible implant, a different corticosteroid, or an implant administered outside the vitreous would fall outside at least some express limitations.

Manufacturing significance of extrusion

The extrusion limitation can be commercially important. It may require evidence about the actual manufacturing process used for the implant. A manufacturer could seek to design around the claim by using compression molding, solvent casting, injection molding, additive manufacturing, or another process.

A process change alone may not avoid all related patents. Earlier or later family members may claim the implant composition, dimensions, release profile, or use without requiring extrusion. Manufacturing changes therefore must be assessed against the entire patent family rather than US 9,012,437 in isolation.

What FDA-approved product is linked to this patent?

Ozurdex is the principal commercial product associated with the claimed technology. It is an intravitreal dexamethasone implant marketed by Allergan, now part of AbbVie.

FDA-approved uses include:

Macular edema following branch retinal vein occlusion or central retinal vein occlusion.
Noninfectious uveitis affecting the posterior segment of the eye.
Diabetic macular edema [2].

The claim language lists macular edema, acute macular degeneration, retinal detachment, and PVR. The FDA label does not make every condition in the patent claim an approved indication. Patent claim coverage and regulatory indication coverage are separate analyses.

What is the Orange Book status of US 9,012,437?

The relevant regulatory product is NDA 022315 for Ozurdex. FDA Orange Book patent listings are product-specific and must be separated from the broader patent family.

The main legal consequences are:

An Orange Book listing can trigger the statutory patent-certification framework for an ANDA.
A Paragraph IV certification can create a patent-infringement action under the Hatch-Waxman Act.
The 30-month stay, if triggered, depends on the timing and content of the patent listing, certification, and litigation.
Expiration of a listed patent removes the patent-based barrier created by that patent, although other patents, regulatory exclusivities, manufacturing controls, or device-related rights may remain relevant.

US 9,012,437 has reached the end of its underlying patent term. Its historical Orange Book presence, if any, does not create an indefinite barrier to approval or launch. Current Orange Book status should be evaluated against the live NDA listing rather than inferred from the existence of the patent family [1, 3].

When did US 9,012,437 lose exclusivity?

The patent’s statutory term ended in 2024 based on the family’s underlying filing and priority structure. Patent term is generally governed by 35 U.S.C. §154 and is ordinarily 20 years from the applicable nonprovisional filing date, subject to patent term adjustment, patent term extension, terminal disclaimers, and other statutory rules [4].

The practical conclusion is that US 9,012,437 is no longer a current blocking patent for a new dexamethasone implant launch. A company considering entry must still review:

Other patents in the Ozurdex family.
Continuation and divisional patents.
Later patents covering applicators or delivery systems.
Manufacturing patents.
Formulation patents with later priority dates.
FDA exclusivity and approval requirements.
Device and combination-product requirements.

What other patents cover Ozurdex or related dexamethasone implants?

The relevant landscape has several layers.

Foundational biodegradable ocular implant patents

The Allergan/Oculex family includes patents directed to biodegradable ocular implants, drug-polymer matrices, implantation methods, and release profiles. Representative family members include:

Patent	General subject
US 7,691,001	Biodegradable ocular implant technology
US 7,767,174	Biodegradable implant and ocular treatment applications
US 8,623,395	Related implant and treatment claims
US 9,012,437	Extruded dexamethasone implant treatment method

These patents should be reviewed through the USPTO Patent Center for continuity, terminal disclaimers, maintenance fees, PTA, and prosecution history [1].

Competing corticosteroid delivery platforms

Ozurdex competes with products using different corticosteroids or delivery mechanisms:

Product	Active drug	Delivery format	Main competitive distinction
Ozurdex	Dexamethasone	Biodegradable intravitreal implant	Shorter-duration corticosteroid delivery
Iluvien	Fluocinolone acetonide	Non-biodegradable intravitreal implant	Long-duration delivery
Retisert	Fluocinolone acetonide	Surgically implanted device	Longer-duration uveitis treatment
Yutiq	Fluocinolone acetonide	Intravitreal implant	Long-duration posterior uveitis treatment
Xipere	Triamcinolone acetonide	Suprachoroidal injectable suspension	Different delivery compartment

These products are not direct literal substitutes under the claims of US 9,012,437 because they use different active ingredients, polymers, delivery locations, or dosage forms. Their patent estates remain relevant to competitive entry but do not directly replace the Ozurdex patent analysis.

What generic entry risks exist for a dexamethasone implant?

A dexamethasone intravitreal implant is more difficult to copy than a conventional small-molecule tablet or ophthalmic solution.

FDA pathway

A generic applicant would generally need an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. Because Ozurdex is a drug-device combination product with an implant delivery system, the applicant may also need to address device performance, implant dimensions, release characteristics, sterility, and administration mechanics.

A 505(b)(2) application could be relevant where the applicant relies partly on FDA findings for the reference product but proposes differences in formulation, delivery system, indication, or clinical data package [5].

Technical barriers

The principal technical barriers are:

Reproducing the release profile in the vitreous.
Matching implant degradation behavior.
Demonstrating equivalent dexamethasone exposure.
Establishing sterility and particulate controls.
Matching the applicator and deployment process.
Showing consistent extrusion or alternative manufacturing performance.
Demonstrating acceptable ocular safety.
Supporting equivalence despite the implant’s local, long-acting delivery.

A design-around product could use a different PLGA ratio, a different polymer, a different implant mass, or a different manufacturing process. That approach may avoid US 9,012,437 but still face FDA comparability requirements and other patent claims.

Which companies are challenging the Ozurdex patent estate?

The principal commercial patent holder was Allergan, which became part of AbbVie in 2020. Publicly reported ANDA litigation involving Ozurdex or related patents must be verified by case docket, asserted patent, filing date, and settlement terms. The existence of an ANDA or a Paragraph IV certification does not establish that US 9,012,437 was the only patent in dispute.

For transaction or launch analysis, the relevant questions are:

Which patents were listed for NDA 022315?
Which patents were asserted against the applicant?
Was the case dismissed, settled, or litigated to judgment?
Did the settlement include a license date?
Did the agreement restrict manufacturing, API sourcing, or launch timing?
Did the applicant obtain a first-filer advantage or other commercial right?

No conclusion about a current generic launch date should be based solely on US 9,012,437. Its term has ended, and the remaining risk is family-wide and regulatory.

How strong is the patent estate for the claimed technology?

US 9,012,437 had moderate historical strength but narrow claim breadth.

Strengths

It combines composition, manufacturing, implant mass, pharmacokinetic, and indication limitations.
The claim maps closely to a defined commercial delivery system.
The 48-hour and three-week exposure requirements can distinguish conventional dexamethasone formulations.
The extrusion limitation may be useful against copies using the same manufacturing platform.
Dependent claims 2 through 5 provide fallback positions focused on PLGA and drug loading.

Vulnerabilities

Multiple limitations must be proven simultaneously.
The concentration thresholds may create evidentiary disputes.
“About” ranges can create claim-construction questions.
“Equivalent to” may require agreement on the testing methodology.
The extrusion limitation creates a potential process-based design-around.
The listed disease conditions do not track every FDA-approved Ozurdex indication.
Prior art concerning biodegradable ocular implants and dexamethasone could have supported validity challenges.
The patent term has expired.

The strongest historical enforcement position would have involved a product closely matching the Ozurdex implant in polymer, mass, extrusion process, loading, and release profile. The weakest position would involve a different steroid, non-PLGA polymer, materially different implant mass, alternate manufacturing process, or administration outside the vitreous.

What licensing deals affect this patent landscape?

Allergan acquired Oculex Pharmaceuticals and its biodegradable ocular drug-delivery technology in 2003. The transaction transferred the platform that supported later products including Ozurdex. AbbVie acquired Allergan in 2020, placing the relevant commercial rights within AbbVie’s pharmaceutical portfolio.

The public acquisition history is more important than a later third-party license for ownership analysis. Any freedom-to-operate review should confirm whether specific patents were assigned, licensed, subject to field-of-use restrictions, or encumbered by government rights through USPTO assignment records and transaction documents.

Key Takeaways

US 9,012,437 covers a specific intravitreal dexamethasone implant treatment method.
The claim requires a bioerodible dexamethasone-polymer implant, extrusion manufacture, a 500-1,000 microgram total mass, and defined vitreous exposure levels.
Dependent claims narrow the polymer to PLGA, then to 50/50 PLGA, and finally to 50%-80% dexamethasone loading.
The patent is closely associated with the Ozurdex technology platform.
The claim does not cover all ocular dexamethasone products or all corticosteroid implants.
The patent term ended in 2024, eliminating it as a current standalone launch barrier.
Remaining entry risk depends on other family patents, later patents, Orange Book listings, FDA requirements, and implant manufacturing equivalence.
A competing product using a different steroid, polymer, implant mass, delivery location, or manufacturing process may avoid literal infringement, but must still address regulatory and technical barriers.
Historical Paragraph IV and litigation analysis must be performed across the entire Ozurdex patent estate, not from US 9,012,437 alone.

FAQs About US Patent 9,012,437

Does US 9,012,437 cover Ozurdex?

It covers a method that closely tracks the core characteristics of Ozurdex, including intravitreal dexamethasone delivery from a bioerodible implant. Product-specific infringement requires analysis of every claim limitation.

Does the patent cover dexamethasone eye drops?

No. The claims require implantation into the vitreous of the eye. Topical dexamethasone drops do not satisfy that limitation.

Can a non-PLGA dexamethasone implant avoid the patent?

It may avoid claims 2 and 3, but claim 1 is not expressly limited to PLGA. The full claim, including the delivery profile, extrusion process, and implant mass, must be evaluated.

Does patent expiration eliminate FDA approval requirements?

No. Patent expiration removes the patent barrier but does not eliminate ANDA, 505(b)(2), device-performance, sterility, bioequivalence, or clinical requirements.

Is a biosimilar pathway relevant to Ozurdex?

No. Dexamethasone is a chemically synthesized small molecule, and Ozurdex is regulated as a drug-device combination product. A generic or 505(b)(2) pathway is generally more relevant than a biosimilar pathway.

References

United States Patent and Trademark Office. (2015). US Patent No. 9,012,437, Biodegradable implants for treating ocular conditions. USPTO Patent Center.
U.S. Food and Drug Administration. (n.d.). Ozurdex prescribing information. FDA.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
United States Code. (2024). 35 U.S.C. § 154: Contents and term of patent; provisional rights.
U.S. Food and Drug Administration. (2022). Applications covered by section 505(b)(2). FDA.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	029567	⤷ Start Trial
Austria	339185	⤷ Start Trial
Australia	2001273166	⤷ Start Trial
Australia	2005246995	⤷ Start Trial
Australia	7316601	⤷ Start Trial
Brazil	0112361	⤷ Start Trial
Canada	2414680	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,012,437

Summary for Patent: 9,012,437